Protocol Ledger

NCT04423211 · Phase III · RECRUITING

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Interventional Phase III clinical trial protocol NCT04423211 sponsored by ECOG-ACRIN Cancer Research Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-10-08 Enrollment: 804 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04423211
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)804 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04423211
Protocol FieldVerified Registry Value
NCT IdentifierNCT04423211
Consolidated Lead SponsorECOG-ACRIN Cancer Research Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment804 participants (ESTIMATED)
Registered Start Date2020-10-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI